Therapeutic Antibodies

Question 1

Alemtuzumab: target, use

Answer 1

CD52; CLL

“aLYMtuzumab” - chronic LYMphocytic leukemia

Question 2

Bevacizumab: target, use

Answer 2

VEGF; Colorectal cancer, renal cell carcinoma

Question 3

Cetuximab: target, use

Answer 3

EGFR; Stage IV colorectal cancer, head and neck cancer

Question 4

Rituximab: target, use

Answer 4

CD20; B-cell non-Hodgkin lymphoma, RA (w/MTX), ITP

Question 5

Trastuzumab: target, use

Answer 5

HER2/neu; Breast cancer, gastric cancer

HER2 - “tras2zumab”

Question 6

Infliximab, Adalimumab

Answer 6

TNF-alpha; IBD RA, Ankylosing spondylitis, psoriasis

Rheumatoid arthritis “inflix” pain in “da limbs”

Question 7

Natalizumab: target, use

Answer 7

alpha4-integrin; Multiple sclerosis, Crohn Disease
Alpha4-integrin: leukocyte adhesion
Risk of PML in pts with JC virus

Question 8

Abciximab: target, use

Answer 8

Glycoprotein IIb/IIIa;
Antiplatelet agent for prevention of ischemic complications in pts undergoing percutaneous coronary intervention
IIb times IIIz equals “abSIXimab”

Question 9

Denosumab: target, use

Answer 9

RANKL
Osteoporosis; inhibits osteoclast maturation (mimics osteoprotegrin)
denOSumab affects OSteoclasts

Question 10

Digoxin immune Fab: target, use

Answer 10

Digoxin

Antidote for digoxin toxicity

Question 11

Omalizumab: target, use

Answer 11

IgE

Allergic asthma; prevents IgE binding to FCeRI

Question 12

Palivizumab: target, use

Answer 12

RSV F protein
RSV prophylaxis for high-risk infants
PaliVIzumab - VIrus